The role of *H. pylori* in the complicated peptic ulcer disease, particularly perforated duodenal ulcer has been emphasized by various studies. Kumar and Sinha in their study on patients who underwent surgery for perforated duodenal ulcer found that active duodenal ulcer was significantly higher in patients who had *H. pylori* infection in the postoperative follow up endoscopy and concluded that *H. pylori* was the single most important factor for the persistence of ulcer after surgery.\[[@ref1]\] Mihmanli *et al*. studied patients of perforated duodenal ulcer who underwent bilateral truncal vagotomy and Weinberg pyloroplasty along with excision of ulcer with the pyloric ring, and found that *H. pylori* was present throughout the wall of the ulcer and noticed the high ratio of *H. pylori*-positive antral biopsy in these patients indicating the importance of eradicating this organism in the complicated peptic ulcer disease patients.\[[@ref2]\] The International Agency for Research on cancer, classified *H. pylori* as a definite carcinogen and recommends eradication of this organism in all the positive cases. Although there is no documentation to suggest that patients of perforated duodenal ulcer have more virulent organisms, the eradication of *H. pylori* to prevent ulcer recurrence after duodenal ulcer perforation has been shown to be effective, in other studies.\[[@ref3][@ref4][@ref5]\]

The standard triple therapy (STT) treatment regimen, which includes proton pump inhibitors (PPI), clarithromycin, and amoxicillin or metronidazole, proposed at the first Maastricht conference to treat *H. pylori* infection has become universally accepted and is being widely used for eradication of *H. pylori*, especially in developing countries.\[[@ref6]\] Vaira *et al*. have reported an inconsistent eradication rate of *H. pylori* infection with STT.\[[@ref7]\] Recently Graham and Fischbach showed that among the studies published regarding STT, 60% of the studies failed to reach 80% treatment success, and only 18% had treatment success exceeding 85%.\[[@ref8]\] Several other investigators from the West have reported low eradication rates for STT. With the emergence of antibiotic-resistant strains, newer regimens to achieve higher eradication rate became necessary.

Sequential therapy (ST) with four drugs is defined as use of one PPI and amoxicillin for first 5 days followed by PPI plus clarithromycin and metronidazole for next 5 days.\[[@ref9]\] Several studies have shown that ST was more effective than STT.\[[@ref6][@ref10][@ref11]\] Concomitant therapy (CT) is defined as the use of one PPI, clarithromycin, metronidazole, and amoxicillin for 10 days and is found to have a higher eradication rate than STT.\[[@ref12]\]

There are limited studies comparing the eradication rates for *H. pylori* between ST and CT especially in developing countries like India, where the burden of *H. pylori* infection is much more than that of developed countries. Although there were reports comparing ST and CT for eradication of *H. pylori*, no reports are available in the literature comparing the efficacy of ST with CT in the prevention of ulcer recurrence in patients with duodenal ulcer perforation following simple closure.\[[@ref13]\] Hence, this study was undertaken to compare the efficacy, safety profile, compliance between ST and CT for the eradication of *H. pylori*, and the prevention of ulcer recurrence in patients with duodenal ulcer perforation following simple closure.

METHODS {#sec1-1}
=======

This study was carried out in the Department of Surgery in a tertiary care hospital over a period of two years. The study included all consecutive patients who presented to the Institute\'s Emergency Medical Services with perforated duodenal ulcer and underwent emergency laparotomy with simple closure and were found to be positive for *H. pylori* infection. Positivity for *H. pylori* infection was diagnosed in these patients at their third-month visit following surgery. Patients were advised to stop the PPI at least 8 weeks before the endoscopy.

Exclusion criteria included patients who were found to have perforated gastric ulcer, who had undergone any other procedure apart from the simple closure for duodenal ulcer perforation, re-perforations, those who had associated upper gastrointestinal diseases, and those who had undergone any definitive surgery for peptic ulcer disease.

The study was designed as a prospective parallel arm randomized controlled trail. Block randomization was done using computer program with randomly selected block sizes of 4 and 6. Allocation concealment was ensured by serially numbered opaque sealed envelope (SNOSE). The sample size was calculated using OPENEPI^®^ software. Considering the detection of eradication rate more than 15% between the two regimens on two--tail basis with 95% confidence interval and power of the study \>80% and expected drop out rate of 10%, the sample size was calculated to be 35 in each group. A *P* value \< 0.05 was considered significant.

All patients meeting the inclusion criteria were subjected to upper gastrointestinal endoscopy after getting informed written consent. A 2% lignocaine viscous is used as a local anesthetic allowing a contact time of 5 min. Biopsies were taken from antrum and corpus (two each from both sites) using endoscopic biopsy forceps. One biopsy specimen from antrum and corpus was used for urease test while two other were for Giemsa staining. All endoscopies were done by experienced consultant endoscopists in our department.

Diagnosis of *H. pylori* infection was done by urease test and histology by Giemsa stain. Urease test was done using a solution standardized in our institute.\[[@ref14]\] Two gastric mucosal biopsies were put in the solution at room temperature for 24 h. Urease test was considered positive for *H. pylori* infection when the color of the solution changed from yellow to pink. The patient was considered positive for *H. pylori* status if either or both the tests were positive for *H. pylori*. The patient was considered negative for *H. pylori* infection if both tests were negative.

*H. pylori*-positive patients were randomized into two groups using the opaque sealed envelope technique. One group received ST while the other received CT. ST comprised omeprazole 20 mg twice a day and amoxicillin 1 gm twice a day for the first five days and omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day and metronidazole 400 mg thrice a day for the next five days. Total duration of treatment was 10 days. CT comprised omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, amoxicillin 1 gm twice a day, and metronidazole 400 mg thrice a day for 10 days.

Compliance and side effects were assessed after finishing anti-*H. pylori* therapy by semi-structured interview method allowing the patients to state the reason for noncompliance and side effects in addition to those mentioned in the questionnaires. Patient compliance was assessed as to what extent patient adhered to the schedule and duration of treatment. Patients who did not follow the schedule or those who could not complete the prescribed duration of treatment were considered as noncompliant. A follow-up of these patients was done at 3, 6, and 12 months after index endoscopy. Upper gastrointestinal endoscopy was done to assess the eradication rate of *H. pylori* following ST and CT at three-month follow-up. Ulcer recurrence was noted during follow-up endoscopies.

This study was approved by the Institute\'s Research Council and the Ethics Committee. The nature, methodology, and risks involved in the study were explained to the patients and an informed consent was obtained. All the information collected was kept confidential and patients were given full freedom to withdraw at any point during the study. All provisions of the Declaration of Helsinki were followed in this study.

Statistical analysis {#sec2-1}
--------------------

Statistical analysis was done using GraphpadInstat Software version 3.0 (Graphpad, San Diego, CA, USA). Fisher\'s exact test was used to analyze *H. pylori* eradication, ulcer recurrence, side effects of ST and CT, and for the assessment of compliance of regimens. A *P* value \< 0.05 was considered to be significant. Results were reported in intention-to-treat (ITT), modified intention-to-treat (mITT), and per-protocol (PP) analysis. In mITT lost in follow-up patients were excluded from the analysis.

RESULTS {#sec1-2}
=======

In the present study out of 105 patients present for initial endoscopy, 68 patients were *H. pylori* positive (64.76%) \[[Figure 1](#F1){ref-type="fig"}\]. The mean age in ST and CT group was 44.11 ± 13.75 and 42.45 ± 13.65 years, respectively. The male-to-female ratio in both the groups did not vary significantly (91/9% vs 88/12%; *P* = 0.7053).

![The overall scheme as per CONSORT flowchart. DU = Duodenal ulcer, *H. pylori* = *Helicobacter pylori*, ST = Sequential therapy; CT = Concomitant therapy; UGIE = Upper gastrointestinal endoscopy; ER = Eradication rate. \*Allocation concealment was done by opaque sealed envelope method](SJG-22-309-g001){#F1}

The eradication rate of *H. pylori* in perforated duodenal ulcer patients treated with ST and CT was 71.43% vs 81.80% (*P* = 0.39) by ITT. By mITT the eradication with ST and CT was 78.13% versus 84.37% (*P* = 0.75) and by PP analysis it was 86.20% versus 90% (*P* = 0.71) \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparing the *Helicobacter pylori* eradication rates with the sequential therapy and the concomitant therapy

![](SJG-22-309-g002)

Ulcer recurrence rates in ST groups and CT groups were (17.14% vs 6.06%, *P* = 0.26) and (3.17% vs 0%; *P* = 0.49) at 3 months, (22.86% vs 9.09%, *P* = 0.19) and (6.90% vs 3.33%; *P* = 0.6) at 6 months, and (25.71% vs 15.15%; *P* = 0.37) and (10.34% vs 6.67%; *P* = 0.67) at 1 year of follow-up by ITT and PP analysis, respectively \[[Figure 2](#F2){ref-type="fig"}\]. None of the *H. pylori* eradicated patients had ulcer recurrence. In *H. pylori* failure patients, ulcer recurrence in ST groups and CT groups were (90% vs 75%, *P* = 0.63) and (83% vs 66%, *P* = 0.71) at 1 year of follow up by ITT and PP analysis. Compliance in ST and CT groups was 90.62% and 96.77% (*P* = 0.61), respectively \[[Table 2](#T2){ref-type="table"}\]. Most common side effects in ST and CT were diarrhea (27.59%) and metallic taste (26.67%), respectively \[[Table 3](#T3){ref-type="table"}\]. The cost of a complete course of ST was 570 INR and 1080 INR for CT.

![Comparison of ulcer recurrence following sequential therapy and concomitant therapy at 3, 6, and 12 months by PP = Per-protocol, ITT = Intention-to-treat, mITT = Modified intention-to-treat analysis, CT = Concomitant therapy, ST = Sequential therapy](SJG-22-309-g003){#F2}

###### 

Comparison of the compliance between the sequential therapy and the concomitant therapy per protocol and intention-to-treat analysis
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###### 

Comparison of side effects in the sequential therapy with those in the concomitant therapy group

![](SJG-22-309-g005)

DISCUSSION {#sec1-3}
==========

*H. pylori* prevalence in perforated duodenal ulcer varies in different parts of the world. Earlier reports from this institute showed a prevalence of *H. pylori* infection in perforated duodenal ulcer ranging from 56% to 65%.\[[@ref5][@ref15][@ref16]\] *H. pylori* prevalance in the present study was 64.76%. In the present study, ST achieved an eradication of 71.43%, 78.13%, and 86.20% by ITT, mITT, and PP analyses, respectively. An earlier study done in our institute showed an eradication rate of 73% and 87% by ITT and PP analysis, respectively, with ST where amoxicillin was used in the second phase.\[[@ref16]\] In the present study, instead of amoxicillin, we used metronidazole during the second 5 days of ST. Another study in India showed ITT and PP eradication rates of 76% and 84.6%, respectively, with ST.\[[@ref17]\] In a study done by Vaira *et al*., ST achieved an eradication rate of 89%, 91%, and 93% by ITT, mITT, and PP analysis, respectively.\[[@ref7]\] A meta-analysis by Gatta *et al*. of 46 studies showed an overall eradication rate of 84.3% by ST.\[[@ref9]\]

Wu *et al*., Molina-Infante *et al*., and Kongchayanun *et al*. evaluated 10-day CT against *H. pylori*, which showed ITT eradication rates of 93%, 87%, and 96%, and PP eradication rates of 93%, 89%, and 96%, respectively.\[[@ref13][@ref18][@ref19]\] Georgopoulos *et al*. Showed that CT achieved ITT and PP eradication rates of 91.6% and 94.5%, respectively.\[[@ref12]\] In the present study, CT group achieved ITT, mITT, and PP eradication rates of 81.80%, 84.37%, and 90%, respectively. A meta-analysis of 19 studies involving 2070 patients by Gisbert and Calvet revealed *H. pylori* eradication rate of 88% by ITT analysis.\[[@ref20]\]

McNicholl *et al*. compared the eradication rates of CT and ST and found that CT has a better eradication rate (91% vs 86% by ITT and 87% vs 81% by PP analysis), but not statistically significant.\[[@ref21]\] Wu *et al*. in their study found equal effectiveness for both the therapies.\[[@ref13]\] Lim *et al*. concluded that two-week ST and CT were of suboptimal efficacy.\[[@ref22]\] In a study done in Palestine, Abu-Safieh failed to show an acceptable eradication by both ST and CT.\[[@ref23]\] A meta-analysis of six studies comparing ST with CT (1039 vs 1031 patients) showed an eradication rate of 81.7% and 81.3%, respectively.\[[@ref9]\] In the present study, CT achieved better eradication rates compared with ST, but this did not achieve statistical significance. Primary clarithromycin and metronidazole resistance rates in India are 33% and 78%, respectively, which are higher than in other countries. Metronidazole has been used as a part of standard ST and CT regimen in majority of the studies. Although metronidazole resistance is more prevalent compared with the other drugs used for *H. pylori* eradication, it has not changed over the years. It is also emphasized that metronidazole resistance has less impact in *H. pylori* eradication therapy than that of the clarithromycin resistance and this resistance can be overcome by increasing the dose and the duration of the treatment.\[[@ref24][@ref25]\] This high rate of antimicrobial resistance is probably because of injudicious use of antibiotics for various diseases.

Ulcer recurrence rates are highly variable in different studies in different parts of the world.\[[@ref26][@ref27]\] In an earlier study conducted in our institute, Bose *et al*. found out that eradication of *H. pylori* infection in patients with perforated duodenal ulcer, treated with simple closure, decreases the rate of ulcer recurrence significantly.\[[@ref5]\] In the present study, the differences in ulcer recurrence rates between the two groups at 3, 6, and 12 months by ITT, mITT, and PP analysis were not statistically significant. High recurrence rates in both the ST and CT might be due to noncompliance to treatment or might be due to re-infection of *H. pylori* as a result of poor socioeconomic conditions. A study with more number of study subjects is needed to get a broader picture of ulcer recurrence following ST and CT.

Compliance in ST and CT groups were 90.62% and 96.77%, respectively. CT group has better compliance, but the difference was not statistically significant. In a study by Wu *et al*. compliance in ST and CT were 95.7% and 98.2%.\[[@ref13]\] Lim *et al*. in their study showed a better compliance with CT than ST (95.3% vs. 96.2%; *P* value = 0.80).\[[@ref22]\] Lesser compliance for both CT and ST (82.7% vs 82.4%; *P* value = 0.93) was shown in a study by McNicholl *et al*.\[[@ref21]\] Even though ST is having lesser number of tablets, its complex dosage schedule makes its use difficult for the patient. The success in eradication of *H. pylori* using ST was postulated to be because of its sequential nature of dosage schedule and due to increase in the number of antibiotics. Hence, if compliance is not maintained in ST, the effectiveness of the therapy will decrease. Higher compliance for CT seen in this study might be due to less complex dosage schedule.

Most common side effects in ST and CT were diarrhea (27.59%) and metallic taste (26.67%), respectively. There was no statistically significant difference in side effects profile between the two groups. Wu *et al*. in their study found bad taste (15.7%) as a major side effect in the concomitant group and fatigue in sequential group (11%).\[[@ref13]\] Diarrhea was the major side effect in both ST and CT groups in a study done by De Francesco *et al*.\[[@ref28]\] Kongchayanun *et al*. in their study found bitter taste, epigastric soreness, and diarrhea as the most common side effects in both groups.\[[@ref19]\]

The cost of a complete course of ST was 570 INR and 1080 INR for CT. ST was economically better than CT. *H. pylori* eradication with CT and ST shows a wide variation in different parts of the world. This difference might be due to the difference in regional antibiotic resistance patterns against *H. pylori*. Based on Graham *et al*.\'s proposed report card to grade *H. pylori* eradication regimen, except study by De Francesco *et al*. for CT, none of the studies got grade A result, which is deemed acceptable for prescription in clinical practice \[[Table 4](#T4){ref-type="table"}\].

###### 

Comparison of *Helicobacter pylori* eradication rate between concomitant therapy and sequential therapy in various studies by per protocol and intention-to-treat analysis

![](SJG-22-309-g006)

CONCLUSION {#sec1-4}
==========

In the present study, it was found that the *H. pylori* eradication rates with ST and CT were similar. The ulcer recurrence rates in both the groups were comparable. Both the regimens have comparable compliance and side effects profile. Hence ST can be considered as a better economical option than CT in the treatment of *H. pylori* infection.

As the prevalence of *H. pylori* is high in developing countries such as India, and various studies showing unacceptable eradication rates, therapy based on antibiotic sensitivity pattern needs to be prescribed for *H. pylori* eradication. Research on developing newer molecules for the eradication of *H. pylori* is required as clarithromycin-based regimen is losing its charm as a potential killer of *H. pylori*.

Study highlights {#sec2-2}
----------------

Standard triple therapy is no longer preferred as the first treatment of choice for *H. pylori* eradicationNewer *H. pylori* eradication regimen such as sequential therapy and concomitant therapy are in the horizon for the past few years with inconsistent resultsIn the present study, it was found that sequential therapy and concomitant therapy have similar eradication rates and ulcer recurrence ratesSequential therapy is an economically better option than concomitant therapy especially in developing countries such as India.

Limitation of the study {#sec2-3}
-----------------------

Antibiotic sensitivity and resistance pattern could not be anayzed for *H. pylori* in the present study.
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